Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has received an average rating of “Hold” from the nine research firms that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $25.33.

LXRX has been the subject of several recent research reports. Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. Wedbush reissued an “ourperform” rating and issued a $39.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday, August 7th. BidaskClub lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, August 1st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $21.00 price objective on shares of Lexicon Pharmaceuticals in a report on Sunday, September 17th.

In other news, insider Lonnel Coats acquired 30,000 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The stock was bought at an average price of $12.54 per share, with a total value of $376,200.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.77% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in LXRX. Parametric Portfolio Associates LLC purchased a new position in Lexicon Pharmaceuticals during the 2nd quarter valued at about $182,000. First Mercantile Trust Co. grew its holdings in Lexicon Pharmaceuticals by 11.2% during the 2nd quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 1,227 shares in the last quarter. Cim Investment Mangement Inc. purchased a new position in Lexicon Pharmaceuticals during the 2nd quarter valued at about $262,000. Pacad Investment Ltd. purchased a new position in Lexicon Pharmaceuticals during the 2nd quarter valued at about $265,000. Finally, Legal & General Group Plc grew its holdings in Lexicon Pharmaceuticals by 2.6% during the 2nd quarter. Legal & General Group Plc now owns 18,570 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 465 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Lexicon Pharmaceuticals, Inc. (LXRX) Given Consensus Recommendation of “Hold” by Analysts” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/25/lexicon-pharmaceuticals-inc-lxrx-given-consensus-recommendation-of-hold-by-analysts.html.

Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at 10.57 on Wednesday. The firm has a 50 day moving average of $12.39 and a 200 day moving average of $14.72. The firm’s market capitalization is $1.12 billion. Lexicon Pharmaceuticals has a 12-month low of $10.55 and a 12-month high of $18.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.12. The company had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $18.34 million. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The business’s revenue for the quarter was down 40.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.37) EPS. On average, analysts forecast that Lexicon Pharmaceuticals will post ($1.47) EPS for the current fiscal year.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.